As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...

It's more important than ever before for your elected officials to hear from you - don't miss your chance to turn Capitol ...

Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...

In a new study, researchers examined herbal supplements with immune-activating properties that could trigger or worsen ...

Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the ...

Investigators compared the risk of cancer onset in patients with lupus nephritis treatedwith calcineurin inhibitors vs ...

A regulatory decision is expected by October 2025. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva ®) for the ...

Please provide your email address to receive an email when new articles are posted on . Victoria P. Werth, MD, professor of dermatology at the University of Pennsylvania Hospital, and chief of ...

INDIANAPOLIS (WISH) — Lupus is a chronic autoimmune condition affecting 1.5 millions Americans and 5 million individuals globally. This week, the American College of Rheumatology released updated ...

Lupus is often marked by flares, which is when symptoms are usually more obvious.

Please provide your email address to receive an email when new articles are posted on . None of the eligible trials received a “good” diversity rating for race and ethnicity. Access-related barriers ...

Lupus affects women at disproportionately high rates— roughly 9 out of 10 patients are female —and research consistently ...